CA3039927C - Treating steroid dependent lupus nephritis using a composition that inhibits masp-2 dependent complement activation - Google Patents

Info

Publication number

CA3039927C

CA3039927C CA3039927A CA3039927A CA3039927C CA 3039927 C CA3039927 C CA 3039927C CA 3039927 A CA3039927 A CA 3039927A CA 3039927 A CA3039927 A CA 3039927A CA 3039927 C CA3039927 C CA 3039927C

Authority

CA

Canada

Prior art keywords

masp

antibody

inhibitory

fibrosis

seq

Prior art date

2016-10-13

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Active

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 230000024203 complement activation Effects 0.000 title claims abstract description 81
• 239000000203 mixture Substances 0.000 title claims abstract description 79
• 230000001419 dependent effect Effects 0.000 title claims abstract description 72
• 208000005777 Lupus Nephritis Diseases 0.000 title claims abstract description 36
• 150000003431 steroids Chemical class 0.000 title claims abstract description 15
• 230000002401 inhibitory effect Effects 0.000 claims abstract description 318
• 241000282414 Homo sapiens Species 0.000 claims abstract description 106
• 230000027455 binding Effects 0.000 claims abstract description 98
• 239000012634 fragment Substances 0.000 claims abstract description 84
• 239000000427 antigen Substances 0.000 claims abstract description 53
• 108091007433 antigens Proteins 0.000 claims abstract description 53
• 102000036639 antigens Human genes 0.000 claims abstract description 53
• 101001056015 Homo sapiens Mannan-binding lectin serine protease 2 Proteins 0.000 claims abstract description 44
• 102000054960 human MASP2 Human genes 0.000 claims abstract description 44
• 101710117460 Mannan-binding lectin serine protease 2 Proteins 0.000 claims abstract 15
• 102100026046 Mannan-binding lectin serine protease 2 Human genes 0.000 claims abstract 15
• 108090000623 proteins and genes Proteins 0.000 claims description 88
• 102000004169 proteins and genes Human genes 0.000 claims description 70
• 230000008021 deposition Effects 0.000 claims description 40
• 210000002700 urine Anatomy 0.000 claims description 40
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 39
• 230000009467 reduction Effects 0.000 claims description 37
• 230000006870 function Effects 0.000 claims description 36
• 238000011282 treatment Methods 0.000 claims description 36
• 239000003814 drug Substances 0.000 claims description 34
• 230000007423 decrease Effects 0.000 claims description 24
• 230000029142 excretion Effects 0.000 claims description 21
• 230000003907 kidney function Effects 0.000 claims description 19
• 210000002966 serum Anatomy 0.000 claims description 16
• 239000012636 effector Substances 0.000 claims description 15
• 238000004519 manufacturing process Methods 0.000 claims description 15
• 230000002829 reductive effect Effects 0.000 claims description 15
• 239000003246 corticosteroid Substances 0.000 claims description 9
• 102000004856 Lectins Human genes 0.000 abstract description 90
• 108090001090 Lectins Proteins 0.000 abstract description 90
• 230000037361 pathway Effects 0.000 abstract description 89
• 239000002523 lectin Substances 0.000 abstract description 87
• 201000002793 renal fibrosis Diseases 0.000 abstract description 34
• 230000004154 complement system Effects 0.000 abstract description 31
• 108700034225 EC 3.4.21.104 Proteins 0.000 description 499
• 239000003795 chemical substances by application Substances 0.000 description 194
• 206010016654 Fibrosis Diseases 0.000 description 162
• 108090000765 processed proteins & peptides Proteins 0.000 description 162
• 230000004761 fibrosis Effects 0.000 description 157
• 238000000034 method Methods 0.000 description 145
• 230000004054 inflammatory process Effects 0.000 description 102
• 102000004196 processed proteins & peptides Human genes 0.000 description 101
• 206010061218 Inflammation Diseases 0.000 description 100
• 241000699670 Mus sp. Species 0.000 description 83
• 108010087870 Mannose-Binding Lectin Proteins 0.000 description 78
• 102000009112 Mannose-Binding Lectin Human genes 0.000 description 78
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 77
• 235000018102 proteins Nutrition 0.000 description 66
• 201000010099 disease Diseases 0.000 description 50
• 239000003112 inhibitor Substances 0.000 description 48
• 229920001184 polypeptide Polymers 0.000 description 48
• 208000017169 kidney disease Diseases 0.000 description 46
• 235000001014 amino acid Nutrition 0.000 description 45
• 210000003734 kidney Anatomy 0.000 description 45
• 229940024606 amino acid Drugs 0.000 description 42
• 150000001413 amino acids Chemical class 0.000 description 42
• 230000004913 activation Effects 0.000 description 41
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 38
• 210000001519 tissue Anatomy 0.000 description 38
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 37
• 229940098773 bovine serum albumin Drugs 0.000 description 37
• 230000000295 complement effect Effects 0.000 description 37
• 201000001474 proteinuria Diseases 0.000 description 34
• 108090000062 ficolin Proteins 0.000 description 33
• 208000024891 symptom Diseases 0.000 description 32
• 208000010159 IgA glomerulonephritis Diseases 0.000 description 31
• 206010039710 Scleroderma Diseases 0.000 description 31
• 208000020832 chronic kidney disease Diseases 0.000 description 28
• 238000003776 cleavage reaction Methods 0.000 description 27
• 208000035475 disorder Diseases 0.000 description 27
• 230000014509 gene expression Effects 0.000 description 26
• 230000007017 scission Effects 0.000 description 26
• 210000004027 cell Anatomy 0.000 description 25
• 230000006378 damage Effects 0.000 description 25
• 229940079593 drug Drugs 0.000 description 25
• 208000005069 pulmonary fibrosis Diseases 0.000 description 25
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 25
• 230000015572 biosynthetic process Effects 0.000 description 24
• 206010046406 Ureteric obstruction Diseases 0.000 description 23
• 150000007523 nucleic acids Chemical class 0.000 description 23
• 238000003556 assay Methods 0.000 description 22
• 230000003176 fibrotic effect Effects 0.000 description 22
• 208000015181 infectious disease Diseases 0.000 description 22
• 239000002773 nucleotide Substances 0.000 description 22
• 125000003729 nucleotide group Chemical group 0.000 description 22
• 102100024521 Ficolin-2 Human genes 0.000 description 21
• 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 20
• 102000012479 Serine Proteases Human genes 0.000 description 20
• 108010022999 Serine Proteases Proteins 0.000 description 20
• 230000037390 scarring Effects 0.000 description 20
• 102100022133 Complement C3 Human genes 0.000 description 19
• 210000004072 lung Anatomy 0.000 description 19
• 102000039446 nucleic acids Human genes 0.000 description 19
• 108020004707 nucleic acids Proteins 0.000 description 19
• 101000901154 Homo sapiens Complement C3 Proteins 0.000 description 18
• 241001529936 Murinae Species 0.000 description 18
• 229940009456 adriamycin Drugs 0.000 description 18
• 230000000692 anti-sense effect Effects 0.000 description 18
• 208000014674 injury Diseases 0.000 description 18
• 238000001990 intravenous administration Methods 0.000 description 18
• 201000006370 kidney failure Diseases 0.000 description 18
• 108091034117 Oligonucleotide Proteins 0.000 description 17
• 229920002477 rna polymer Polymers 0.000 description 17
• 102000053642 Catalytic RNA Human genes 0.000 description 16
• 108090000994 Catalytic RNA Proteins 0.000 description 16
• 206010021263 IgA nephropathy Diseases 0.000 description 16
• 208000001647 Renal Insufficiency Diseases 0.000 description 16
• 230000005764 inhibitory process Effects 0.000 description 16
• 108020004999 messenger RNA Proteins 0.000 description 16
• 210000000056 organ Anatomy 0.000 description 16
• 108091092562 ribozyme Proteins 0.000 description 16
• 238000007920 subcutaneous administration Methods 0.000 description 16
• 208000007342 Diabetic Nephropathies Diseases 0.000 description 15
• 108060003951 Immunoglobulin Proteins 0.000 description 15
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 15
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 15
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 15
• 241001465754 Metazoa Species 0.000 description 15
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
• 239000002299 complementary DNA Substances 0.000 description 15
• 208000033679 diabetic kidney disease Diseases 0.000 description 15
• 238000000502 dialysis Methods 0.000 description 15
• 102000018358 immunoglobulin Human genes 0.000 description 15
• 238000002347 injection Methods 0.000 description 15
• 239000007924 injection Substances 0.000 description 15
• 238000001361 intraarterial administration Methods 0.000 description 15
• 238000007918 intramuscular administration Methods 0.000 description 15
• 230000001404 mediated effect Effects 0.000 description 15
• 230000002263 peptidergic effect Effects 0.000 description 15
• 239000011780 sodium chloride Substances 0.000 description 15
• 238000001356 surgical procedure Methods 0.000 description 15
• 108020004414 DNA Proteins 0.000 description 14
• 102000053602 DNA Human genes 0.000 description 14
• 208000022461 Glomerular disease Diseases 0.000 description 14
• 230000000694 effects Effects 0.000 description 14
• 201000008350 membranous glomerulonephritis Diseases 0.000 description 14
• 238000007911 parenteral administration Methods 0.000 description 14
• 238000011277 treatment modality Methods 0.000 description 14
• 208000019425 cirrhosis of liver Diseases 0.000 description 13
• 231100000852 glomerular disease Toxicity 0.000 description 13
• 210000004408 hybridoma Anatomy 0.000 description 13
• 230000001965 increasing effect Effects 0.000 description 13
• 210000005084 renal tissue Anatomy 0.000 description 13
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 12
• 206010020772 Hypertension Diseases 0.000 description 12
• 208000027418 Wounds and injury Diseases 0.000 description 12
• 238000010191 image analysis Methods 0.000 description 12
• 239000000047 product Substances 0.000 description 12
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 11
• 206010018372 Glomerulonephritis membranous Diseases 0.000 description 11
• -1 H-ficolin Proteins 0.000 description 11
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 11
• 241000700159 Rattus Species 0.000 description 11
• 101001018257 Rattus norvegicus Mannan-binding lectin serine protease 2 Proteins 0.000 description 11
• 238000010171 animal model Methods 0.000 description 11
• 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 11
• 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 description 11
• 231100000855 membranous nephropathy Toxicity 0.000 description 11
• 230000004048 modification Effects 0.000 description 11
• 238000012986 modification Methods 0.000 description 11
• 238000006467 substitution reaction Methods 0.000 description 11
• 238000003786 synthesis reaction Methods 0.000 description 11
• 230000001225 therapeutic effect Effects 0.000 description 11
• 208000029574 C3 glomerulopathy Diseases 0.000 description 10
• 102000008186 Collagen Human genes 0.000 description 10
• 108010035532 Collagen Proteins 0.000 description 10
• 102100024508 Ficolin-1 Human genes 0.000 description 10
• 208000019693 Lung disease Diseases 0.000 description 10
• 102000004528 Mannose-Binding Protein-Associated Serine Proteases Human genes 0.000 description 10
• 108010042484 Mannose-Binding Protein-Associated Serine Proteases Proteins 0.000 description 10
• 108091028043 Nucleic acid sequence Proteins 0.000 description 10
• 230000003510 anti-fibrotic effect Effects 0.000 description 10
• 229920001436 collagen Polymers 0.000 description 10
• 210000002808 connective tissue Anatomy 0.000 description 10
• 201000000523 end stage renal failure Diseases 0.000 description 10
• 210000002540 macrophage Anatomy 0.000 description 10
• 230000035772 mutation Effects 0.000 description 10
• 208000027134 non-immunoglobulin-mediated membranoproliferative glomerulonephritis Diseases 0.000 description 10
• 150000003384 small molecules Chemical class 0.000 description 10
• 208000019553 vascular disease Diseases 0.000 description 10
• 206010018374 Glomerulonephritis minimal lesion Diseases 0.000 description 9
• 208000004883 Lipoid Nephrosis Diseases 0.000 description 9
• 206010029164 Nephrotic syndrome Diseases 0.000 description 9
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
• 150000001720 carbohydrates Chemical class 0.000 description 9
• 235000014633 carbohydrates Nutrition 0.000 description 9
• 230000001684 chronic effect Effects 0.000 description 9
• 150000001875 compounds Chemical class 0.000 description 9
• 208000028208 end stage renal disease Diseases 0.000 description 9
• 210000002216 heart Anatomy 0.000 description 9
• 229940027941 immunoglobulin g Drugs 0.000 description 9
• 230000007170 pathology Effects 0.000 description 9
• 101000651671 Bombyx mori Sex-specific storage-protein 2 Proteins 0.000 description 8
• 208000035473 Communicable disease Diseases 0.000 description 8
• 102100031506 Complement C5 Human genes 0.000 description 8
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
• 208000005176 Hepatitis C Diseases 0.000 description 8
• 241000282412 Homo Species 0.000 description 8
• 101000941598 Homo sapiens Complement C5 Proteins 0.000 description 8
• 101000664506 Homo sapiens Spermatogenesis-associated protein 1 Proteins 0.000 description 8
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 8
• 102100026061 Mannan-binding lectin serine protease 1 Human genes 0.000 description 8
• 241000699666 Mus <mouse, genus> Species 0.000 description 8
• 239000004365 Protease Substances 0.000 description 8
• 206010061481 Renal injury Diseases 0.000 description 8
• 102100038832 Spermatogenesis-associated protein 1 Human genes 0.000 description 8
• 125000000539 amino acid group Chemical group 0.000 description 8
• 239000013604 expression vector Substances 0.000 description 8
• 208000002672 hepatitis B Diseases 0.000 description 8
• 208000019423 liver disease Diseases 0.000 description 8
• 230000004199 lung function Effects 0.000 description 8
• 230000000750 progressive effect Effects 0.000 description 8
• 235000000346 sugar Nutrition 0.000 description 8
• 238000011200 topical administration Methods 0.000 description 8
• 208000037999 tubulointerstitial fibrosis Diseases 0.000 description 8
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 7
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 7
• 208000023275 Autoimmune disease Diseases 0.000 description 7
• 102000004190 Enzymes Human genes 0.000 description 7
• 108090000790 Enzymes Proteins 0.000 description 7
• 208000012659 Joint disease Diseases 0.000 description 7
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 7
• 208000022873 Ocular disease Diseases 0.000 description 7
• 102000035195 Peptidases Human genes 0.000 description 7
• 108091005804 Peptidases Proteins 0.000 description 7
• 239000000074 antisense oligonucleotide Substances 0.000 description 7
• 238000012230 antisense oligonucleotides Methods 0.000 description 7
• 230000000903 blocking effect Effects 0.000 description 7
• 210000004369 blood Anatomy 0.000 description 7
• 239000008280 blood Substances 0.000 description 7
• 206010012601 diabetes mellitus Diseases 0.000 description 7
• 229940088598 enzyme Drugs 0.000 description 7
• 230000003902 lesion Effects 0.000 description 7
• 210000000885 nephron Anatomy 0.000 description 7
• 231100000241 scar Toxicity 0.000 description 7
• 208000017520 skin disease Diseases 0.000 description 7
• 230000002588 toxic effect Effects 0.000 description 7
• 230000001988 toxicity Effects 0.000 description 7
• 231100000419 toxicity Toxicity 0.000 description 7
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 6
• 108020005544 Antisense RNA Proteins 0.000 description 6
• 201000003883 Cystic fibrosis Diseases 0.000 description 6
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 6
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 6
• 206010018364 Glomerulonephritis Diseases 0.000 description 6
• 102000004889 Interleukin-6 Human genes 0.000 description 6
• 108090001005 Interleukin-6 Proteins 0.000 description 6
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 6
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
• 101710098940 Pro-epidermal growth factor Proteins 0.000 description 6
• 102100033237 Pro-epidermal growth factor Human genes 0.000 description 6
• 206010063837 Reperfusion injury Diseases 0.000 description 6
• 201000009594 Systemic Scleroderma Diseases 0.000 description 6
• 206010042953 Systemic sclerosis Diseases 0.000 description 6
• 230000000747 cardiac effect Effects 0.000 description 6
• 230000001413 cellular effect Effects 0.000 description 6
• 238000011161 development Methods 0.000 description 6
• 230000018109 developmental process Effects 0.000 description 6
• 238000010586 diagram Methods 0.000 description 6
• 230000009368 gene silencing by RNA Effects 0.000 description 6
• 238000001727 in vivo Methods 0.000 description 6
• 230000002757 inflammatory effect Effects 0.000 description 6
• 230000000977 initiatory effect Effects 0.000 description 6
• 230000003993 interaction Effects 0.000 description 6
• 229940100601 interleukin-6 Drugs 0.000 description 6
• 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 6
• 102000040430 polynucleotide Human genes 0.000 description 6
• 108091033319 polynucleotide Proteins 0.000 description 6
• 239000002157 polynucleotide Substances 0.000 description 6
• 102000005962 receptors Human genes 0.000 description 6
• 108020003175 receptors Proteins 0.000 description 6
• 231100000331 toxic Toxicity 0.000 description 6
• 238000002054 transplantation Methods 0.000 description 6
• 230000008733 trauma Effects 0.000 description 6
• 241000710929 Alphavirus Species 0.000 description 5
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 5
• 102000004127 Cytokines Human genes 0.000 description 5
• 108090000695 Cytokines Proteins 0.000 description 5
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
• 101000909536 Homo sapiens Collectin-11 Proteins 0.000 description 5
• 241000725303 Human immunodeficiency virus Species 0.000 description 5
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 5
• 206010067125 Liver injury Diseases 0.000 description 5
• 241000124008 Mammalia Species 0.000 description 5
• 101710117390 Mannan-binding lectin serine protease 1 Proteins 0.000 description 5
• 241000283973 Oryctolagus cuniculus Species 0.000 description 5
• 238000004458 analytical method Methods 0.000 description 5
• 230000003302 anti-idiotype Effects 0.000 description 5
• 230000008901 benefit Effects 0.000 description 5
• 230000003247 decreasing effect Effects 0.000 description 5
• 230000007123 defense Effects 0.000 description 5
• 238000013461 design Methods 0.000 description 5
• 210000003743 erythrocyte Anatomy 0.000 description 5
• 210000002950 fibroblast Anatomy 0.000 description 5
• 208000005252 hepatitis A Diseases 0.000 description 5
• 229940099472 immunoglobulin a Drugs 0.000 description 5
• 208000010125 myocardial infarction Diseases 0.000 description 5
• 239000012071 phase Substances 0.000 description 5
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
• 238000003753 real-time PCR Methods 0.000 description 5
• 230000004044 response Effects 0.000 description 5
• 238000011830 transgenic mouse model Methods 0.000 description 5
• 230000014616 translation Effects 0.000 description 5
• LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 4
• 239000005541 ACE inhibitor Substances 0.000 description 4
• 208000020084 Bone disease Diseases 0.000 description 4
• 102100024331 Collectin-11 Human genes 0.000 description 4
• 102000016574 Complement C3-C5 Convertases Human genes 0.000 description 4
• 108010067641 Complement C3-C5 Convertases Proteins 0.000 description 4
• 208000011231 Crohn disease Diseases 0.000 description 4
• 208000001708 Dupuytren contracture Diseases 0.000 description 4
• 201000009273 Endometriosis Diseases 0.000 description 4
• 108700024394 Exon Proteins 0.000 description 4
• 206010019668 Hepatic fibrosis Diseases 0.000 description 4
• 101001052749 Homo sapiens Ficolin-3 Proteins 0.000 description 4
• 208000002260 Keloid Diseases 0.000 description 4
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
• 229920000057 Mannan Polymers 0.000 description 4
• 241000699660 Mus musculus Species 0.000 description 4
• OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 4
• 208000004362 Penile Induration Diseases 0.000 description 4
• 206010034464 Periarthritis Diseases 0.000 description 4
• 208000020758 Peyronie disease Diseases 0.000 description 4
• 206010035226 Plasma cell myeloma Diseases 0.000 description 4
• 206010038748 Restrictive cardiomyopathy Diseases 0.000 description 4
• 206010040943 Skin Ulcer Diseases 0.000 description 4
• 208000016247 Soft tissue disease Diseases 0.000 description 4
• 208000004608 Ureteral Obstruction Diseases 0.000 description 4
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
• 238000009825 accumulation Methods 0.000 description 4
• 239000002253 acid Substances 0.000 description 4
• 230000001154 acute effect Effects 0.000 description 4
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 4
• 230000003143 atherosclerotic effect Effects 0.000 description 4
• 230000001746 atrial effect Effects 0.000 description 4
• 210000000988 bone and bone Anatomy 0.000 description 4
• 201000009267 bronchiectasis Diseases 0.000 description 4
• 230000003197 catalytic effect Effects 0.000 description 4
• 210000003169 central nervous system Anatomy 0.000 description 4
• 230000008859 change Effects 0.000 description 4
• 208000022831 chronic renal failure syndrome Diseases 0.000 description 4
• 230000004087 circulation Effects 0.000 description 4
• 230000007882 cirrhosis Effects 0.000 description 4
• 239000003184 complementary RNA Substances 0.000 description 4
• 239000013078 crystal Substances 0.000 description 4
• 208000010643 digestive system disease Diseases 0.000 description 4
• 238000006471 dimerization reaction Methods 0.000 description 4
• 201000010048 endomyocardial fibrosis Diseases 0.000 description 4
• 230000002255 enzymatic effect Effects 0.000 description 4
• 230000007705 epithelial mesenchymal transition Effects 0.000 description 4
• 210000002744 extracellular matrix Anatomy 0.000 description 4
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
• 229910052737 gold Inorganic materials 0.000 description 4
• 239000010931 gold Substances 0.000 description 4
• 208000019622 heart disease Diseases 0.000 description 4
• 208000006454 hepatitis Diseases 0.000 description 4
• 102000055676 human FCN3 Human genes 0.000 description 4
• 230000001771 impaired effect Effects 0.000 description 4
• 102000006495 integrins Human genes 0.000 description 4
• 108010044426 integrins Proteins 0.000 description 4
• 201000006334 interstitial nephritis Diseases 0.000 description 4
• 210000001117 keloid Anatomy 0.000 description 4
• 239000003446 ligand Substances 0.000 description 4
• 210000004185 liver Anatomy 0.000 description 4
• 206010025135 lupus erythematosus Diseases 0.000 description 4
• 239000011159 matrix material Substances 0.000 description 4
• 230000007246 mechanism Effects 0.000 description 4
• 210000004379 membrane Anatomy 0.000 description 4
• 239000012528 membrane Substances 0.000 description 4
• 239000000178 monomer Substances 0.000 description 4
• 206010028537 myelofibrosis Diseases 0.000 description 4
• 210000000651 myofibroblast Anatomy 0.000 description 4
• 231100000062 no-observed-adverse-effect level Toxicity 0.000 description 4
• 230000008506 pathogenesis Effects 0.000 description 4
• 230000001575 pathological effect Effects 0.000 description 4
• 229960001639 penicillamine Drugs 0.000 description 4
• 230000003285 pharmacodynamic effect Effects 0.000 description 4
• 230000001105 regulatory effect Effects 0.000 description 4
• 230000001850 reproductive effect Effects 0.000 description 4
• 230000008458 response to injury Effects 0.000 description 4
• 206010039073 rheumatoid arthritis Diseases 0.000 description 4
• 230000028327 secretion Effects 0.000 description 4
• 210000004872 soft tissue Anatomy 0.000 description 4
• 238000010561 standard procedure Methods 0.000 description 4
• 239000000126 substance Substances 0.000 description 4
• 150000008163 sugars Chemical class 0.000 description 4
• 230000002194 synthesizing effect Effects 0.000 description 4
• 230000000451 tissue damage Effects 0.000 description 4
• 231100000827 tissue damage Toxicity 0.000 description 4
• 238000013519 translation Methods 0.000 description 4
• 230000001960 triggered effect Effects 0.000 description 4
• 230000029663 wound healing Effects 0.000 description 4
• SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 3
• RYSMHWILUNYBFW-UHFFFAOYSA-N 4-amino-2-[6-(dimethylamino)purin-9-yl]-5-(hydroxymethyl)oxolan-3-ol Chemical compound C1=NC=2C(N(C)C)=NC=NC=2N1C1OC(CO)C(N)C1O RYSMHWILUNYBFW-UHFFFAOYSA-N 0.000 description 3
• 206010001580 Albuminuria Diseases 0.000 description 3
• 208000007848 Alcoholism Diseases 0.000 description 3
• 208000024985 Alport syndrome Diseases 0.000 description 3
• 206010001939 Aminoaciduria Diseases 0.000 description 3
• 239000004475 Arginine Substances 0.000 description 3
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
• 241000894006 Bacteria Species 0.000 description 3
• 241000282472 Canis lupus familiaris Species 0.000 description 3
• 206010007764 Cataract subcapsular Diseases 0.000 description 3
• 108010034358 Classical Pathway Complement C3 Convertase Proteins 0.000 description 3
• 208000029147 Collagen-vascular disease Diseases 0.000 description 3
• 206010061818 Disease progression Diseases 0.000 description 3
• 208000000059 Dyspnea Diseases 0.000 description 3
• 206010013975 Dyspnoeas Diseases 0.000 description 3
• 102000010911 Enzyme Precursors Human genes 0.000 description 3
• 108010062466 Enzyme Precursors Proteins 0.000 description 3
• 208000024720 Fabry Disease Diseases 0.000 description 3
• 206010016207 Familial Mediterranean fever Diseases 0.000 description 3
• 208000026019 Fanconi renotubular syndrome Diseases 0.000 description 3
• 201000006328 Fanconi syndrome Diseases 0.000 description 3
• 108010067306 Fibronectins Proteins 0.000 description 3
• 102000016359 Fibronectins Human genes 0.000 description 3
• 206010018370 Glomerulonephritis membranoproliferative Diseases 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 239000004471 Glycine Substances 0.000 description 3
• 208000032003 Glycogen storage disease due to glucose-6-phosphatase deficiency Diseases 0.000 description 3
• 208000024869 Goodpasture syndrome Diseases 0.000 description 3
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 3
• 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 3
• 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 3
• 206010019851 Hepatotoxicity Diseases 0.000 description 3
• GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 3
• 101001055956 Homo sapiens Mannan-binding lectin serine protease 1 Proteins 0.000 description 3
• 101001056128 Homo sapiens Mannose-binding protein C Proteins 0.000 description 3
• 101001018318 Homo sapiens Myelin basic protein Proteins 0.000 description 3
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 3
• 206010021143 Hypoxia Diseases 0.000 description 3
• 208000031814 IgA Vasculitis Diseases 0.000 description 3
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 3
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 3
• 206010023439 Kidney transplant rejection Diseases 0.000 description 3
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
• 239000004472 Lysine Substances 0.000 description 3
• 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 description 3
• 208000034578 Multiple myelomas Diseases 0.000 description 3
• 208000000175 Nail-Patella Syndrome Diseases 0.000 description 3
• 102000057297 Pepsin A Human genes 0.000 description 3
• 108090000284 Pepsin A Proteins 0.000 description 3
• 206010036346 Posterior capsule opacification Diseases 0.000 description 3
• 208000004318 Schistosomiasis haematobia Diseases 0.000 description 3
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
• 208000021386 Sjogren Syndrome Diseases 0.000 description 3
• 208000006011 Stroke Diseases 0.000 description 3
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
• 239000004473 Threonine Substances 0.000 description 3
• 241000700605 Viruses Species 0.000 description 3
• 229920000392 Zymosan Polymers 0.000 description 3
• 230000002411 adverse Effects 0.000 description 3
• 235000004279 alanine Nutrition 0.000 description 3
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
• 206010001584 alcohol abuse Diseases 0.000 description 3
• 208000025746 alcohol use disease Diseases 0.000 description 3
• 239000003242 anti bacterial agent Substances 0.000 description 3
• 229940088710 antibiotic agent Drugs 0.000 description 3
• 230000000890 antigenic effect Effects 0.000 description 3
• 238000013459 approach Methods 0.000 description 3
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
• 210000002565 arteriole Anatomy 0.000 description 3
• 206010003246 arthritis Diseases 0.000 description 3
• 235000009582 asparagine Nutrition 0.000 description 3
• 229960001230 asparagine Drugs 0.000 description 3
• 230000009286 beneficial effect Effects 0.000 description 3
• 210000004899 c-terminal region Anatomy 0.000 description 3
• 239000011575 calcium Substances 0.000 description 3
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
• 230000009787 cardiac fibrosis Effects 0.000 description 3
• 238000007906 compression Methods 0.000 description 3
• 230000006835 compression Effects 0.000 description 3
• 238000004590 computer program Methods 0.000 description 3
• 230000008602 contraction Effects 0.000 description 3
• 230000000875 corresponding effect Effects 0.000 description 3
• 230000034994 death Effects 0.000 description 3
• 231100000517 death Toxicity 0.000 description 3
• 230000018044 dehydration Effects 0.000 description 3
• 238000006297 dehydration reaction Methods 0.000 description 3
• 229960002069 diamorphine Drugs 0.000 description 3
• 230000029087 digestion Effects 0.000 description 3
• 230000005750 disease progression Effects 0.000 description 3
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 3
• 210000002889 endothelial cell Anatomy 0.000 description 3
• 239000002158 endotoxin Substances 0.000 description 3
• 238000005516 engineering process Methods 0.000 description 3
• 210000002919 epithelial cell Anatomy 0.000 description 3
• 230000004927 fusion Effects 0.000 description 3
• 230000024924 glomerular filtration Effects 0.000 description 3
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
• 150000004676 glycans Chemical class 0.000 description 3
• 201000004541 glycogen storage disease I Diseases 0.000 description 3
• 229940076085 gold Drugs 0.000 description 3
• 210000004247 hand Anatomy 0.000 description 3
• 229910001385 heavy metal Inorganic materials 0.000 description 3
• 201000001505 hemoglobinuria Diseases 0.000 description 3
• 231100000234 hepatic damage Toxicity 0.000 description 3
• 231100000304 hepatotoxicity Toxicity 0.000 description 3
• 230000007686 hepatotoxicity Effects 0.000 description 3
• 208000003215 hereditary nephritis Diseases 0.000 description 3
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
• 102000054064 human MBP Human genes 0.000 description 3
• 229960002591 hydroxyproline Drugs 0.000 description 3
• 230000001631 hypertensive effect Effects 0.000 description 3
• 230000007954 hypoxia Effects 0.000 description 3
• 230000007124 immune defense Effects 0.000 description 3
• 230000028993 immune response Effects 0.000 description 3
• 230000002163 immunogen Effects 0.000 description 3
• 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 3
• 239000003018 immunosuppressive agent Substances 0.000 description 3
• 230000006872 improvement Effects 0.000 description 3
• 238000000338 in vitro Methods 0.000 description 3
• 230000001939 inductive effect Effects 0.000 description 3
• 238000001764 infiltration Methods 0.000 description 3
• 210000004969 inflammatory cell Anatomy 0.000 description 3
• 230000028709 inflammatory response Effects 0.000 description 3
• 229960000310 isoleucine Drugs 0.000 description 3
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
• 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 3
• 229920006008 lipopolysaccharide Polymers 0.000 description 3
• XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 3
• 229910052808 lithium carbonate Inorganic materials 0.000 description 3
• 229940008015 lithium carbonate Drugs 0.000 description 3
• 230000008818 liver damage Effects 0.000 description 3
• 210000004698 lymphocyte Anatomy 0.000 description 3
• 238000005259 measurement Methods 0.000 description 3
• 201000009925 nephrosclerosis Diseases 0.000 description 3
• 231100000637 nephrotoxin Toxicity 0.000 description 3
• 210000000440 neutrophil Anatomy 0.000 description 3
• 229960002715 nicotine Drugs 0.000 description 3
• SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 3
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
• 229940127240 opiate Drugs 0.000 description 3
• 230000036542 oxidative stress Effects 0.000 description 3
• 229960005489 paracetamol Drugs 0.000 description 3
• 229940111202 pepsin Drugs 0.000 description 3
• 238000010647 peptide synthesis reaction Methods 0.000 description 3
• 210000001539 phagocyte Anatomy 0.000 description 3
• 239000008194 pharmaceutical composition Substances 0.000 description 3
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
• 230000006461 physiological response Effects 0.000 description 3
• 230000001144 postural effect Effects 0.000 description 3
• 230000003389 potentiating effect Effects 0.000 description 3
• 201000011461 pre-eclampsia Diseases 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 230000004850 protein–protein interaction Effects 0.000 description 3
• 230000002797 proteolythic effect Effects 0.000 description 3
• 208000002815 pulmonary hypertension Diseases 0.000 description 3
• 238000003259 recombinant expression Methods 0.000 description 3
• 208000017443 reproductive system disease Diseases 0.000 description 3
• 201000000306 sarcoidosis Diseases 0.000 description 3
• 238000012216 screening Methods 0.000 description 3
• 208000007056 sickle cell anemia Diseases 0.000 description 3
• 238000002741 site-directed mutagenesis Methods 0.000 description 3
• 230000009870 specific binding Effects 0.000 description 3
• 230000035882 stress Effects 0.000 description 3
• 208000006379 syphilis Diseases 0.000 description 3
• 229940124597 therapeutic agent Drugs 0.000 description 3
• 208000037816 tissue injury Diseases 0.000 description 3
• FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 3
• 238000013518 transcription Methods 0.000 description 3
• 230000035897 transcription Effects 0.000 description 3
• 230000009261 transgenic effect Effects 0.000 description 3
• 210000004926 tubular epithelial cell Anatomy 0.000 description 3
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
• 201000004410 urinary schistosomiasis Diseases 0.000 description 3
• 208000019206 urinary tract infection Diseases 0.000 description 3
• 239000004474 valine Substances 0.000 description 3
• 230000002792 vascular Effects 0.000 description 3
• 210000001835 viscera Anatomy 0.000 description 3
• 230000003442 weekly effect Effects 0.000 description 3
• WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
• FGMPLJWBKKVCDB-BYPYZUCNSA-N (2s)-1-hydroxypyrrolidine-2-carboxylic acid Chemical compound ON1CCC[C@H]1C(O)=O FGMPLJWBKKVCDB-BYPYZUCNSA-N 0.000 description 2
• 101150028074 2 gene Proteins 0.000 description 2
• 102000009027 Albumins Human genes 0.000 description 2
• 108010088751 Albumins Proteins 0.000 description 2
• 208000002150 Arrhythmogenic Right Ventricular Dysplasia Diseases 0.000 description 2
• 201000006058 Arrhythmogenic right ventricular cardiomyopathy Diseases 0.000 description 2
• 208000006820 Arthralgia Diseases 0.000 description 2
• 206010058029 Arthrofibrosis Diseases 0.000 description 2
• 208000035143 Bacterial infection Diseases 0.000 description 2
• 206010005042 Bladder fibrosis Diseases 0.000 description 2
• 102000004506 Blood Proteins Human genes 0.000 description 2
• 108010017384 Blood Proteins Proteins 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 206010006253 Breast fibrosis Diseases 0.000 description 2
• 241000283707 Capra Species 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• 208000020446 Cardiac disease Diseases 0.000 description 2
• 102000014914 Carrier Proteins Human genes 0.000 description 2
• 108010078791 Carrier Proteins Proteins 0.000 description 2
• 102000019034 Chemokines Human genes 0.000 description 2
• 108010012236 Chemokines Proteins 0.000 description 2
• 206010008909 Chronic Hepatitis Diseases 0.000 description 2
• 208000032544 Cicatrix Diseases 0.000 description 2
• 108091026890 Coding region Proteins 0.000 description 2
• 206010009900 Colitis ulcerative Diseases 0.000 description 2
• 102000004405 Collectins Human genes 0.000 description 2
• 108090000909 Collectins Proteins 0.000 description 2
• 102000000989 Complement System Proteins Human genes 0.000 description 2
• 108010069112 Complement System Proteins Proteins 0.000 description 2
• 101710184994 Complement control protein Proteins 0.000 description 2
• 206010011224 Cough Diseases 0.000 description 2
• 108010069514 Cyclic Peptides Proteins 0.000 description 2
• 102000001189 Cyclic Peptides Human genes 0.000 description 2
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
• 229930105110 Cyclosporin A Natural products 0.000 description 2
• 108010036949 Cyclosporine Proteins 0.000 description 2
• 150000008574 D-amino acids Chemical class 0.000 description 2
• 206010051055 Deep vein thrombosis Diseases 0.000 description 2
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
• 238000002965 ELISA Methods 0.000 description 2
• 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 2
• 208000030820 Ebola disease Diseases 0.000 description 2
• 241000257465 Echinoidea Species 0.000 description 2
• 241000283086 Equidae Species 0.000 description 2
• 208000004930 Fatty Liver Diseases 0.000 description 2
• 229930182566 Gentamicin Natural products 0.000 description 2
• CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
• 102000003886 Glycoproteins Human genes 0.000 description 2
• 108090000288 Glycoproteins Proteins 0.000 description 2
• 201000005624 HELLP Syndrome Diseases 0.000 description 2
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
• 206010019280 Heart failures Diseases 0.000 description 2
• 241000711549 Hepacivirus C Species 0.000 description 2
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
• 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 description 2
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
• 201000003088 Limited Scleroderma Diseases 0.000 description 2
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
• 206010025180 Lymph node fibrosis Diseases 0.000 description 2
• 108700033009 MASP2 Deficiency Proteins 0.000 description 2
• 101100006976 Mus musculus C4b gene Proteins 0.000 description 2
• 206010062575 Muscle contracture Diseases 0.000 description 2
• 206010048654 Muscle fibrosis Diseases 0.000 description 2
• 206010028629 Myoglobinuria Diseases 0.000 description 2
• OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 2
• OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
• MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
• 206010030113 Oedema Diseases 0.000 description 2
• 108700022034 Opsonin Proteins Proteins 0.000 description 2
• 208000002193 Pain Diseases 0.000 description 2
• 241001494479 Pecora Species 0.000 description 2
• 102000007079 Peptide Fragments Human genes 0.000 description 2
• 108010033276 Peptide Fragments Proteins 0.000 description 2
• 206010035600 Pleural fibrosis Diseases 0.000 description 2
• 206010035664 Pneumonia Diseases 0.000 description 2
• 241000288906 Primates Species 0.000 description 2
• LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
• 208000032056 Radiation Fibrosis Syndrome Diseases 0.000 description 2
• 101100400474 Rattus norvegicus Masp2 gene Proteins 0.000 description 2
• 208000012322 Raynaud phenomenon Diseases 0.000 description 2
• 108020004511 Recombinant DNA Proteins 0.000 description 2
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
• 208000017442 Retinal disease Diseases 0.000 description 2
• 206010038923 Retinopathy Diseases 0.000 description 2
• 206010038979 Retroperitoneal fibrosis Diseases 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• 108020004459 Small interfering RNA Proteins 0.000 description 2
• 206010068107 Thyroid fibrosis Diseases 0.000 description 2
• 208000031737 Tissue Adhesions Diseases 0.000 description 2
• 108700019146 Transgenes Proteins 0.000 description 2
• 206010052779 Transplant rejections Diseases 0.000 description 2
• 208000030886 Traumatic Brain injury Diseases 0.000 description 2
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
• 201000006704 Ulcerative Colitis Diseases 0.000 description 2
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
• 206010057469 Vascular stenosis Diseases 0.000 description 2
• 206010047115 Vasculitis Diseases 0.000 description 2
• 206010047249 Venous thrombosis Diseases 0.000 description 2
• 208000002223 abdominal aortic aneurysm Diseases 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• 230000003213 activating effect Effects 0.000 description 2
• 239000012190 activator Substances 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 125000003277 amino group Chemical group 0.000 description 2
• 230000003321 amplification Effects 0.000 description 2
• 206010002022 amyloidosis Diseases 0.000 description 2
• 230000005875 antibody response Effects 0.000 description 2
• 102000025171 antigen binding proteins Human genes 0.000 description 2
• 108091000831 antigen binding proteins Proteins 0.000 description 2
• 208000007474 aortic aneurysm Diseases 0.000 description 2
• 230000001640 apoptogenic effect Effects 0.000 description 2
• 235000003704 aspartic acid Nutrition 0.000 description 2
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
• 210000003719 b-lymphocyte Anatomy 0.000 description 2
• 230000001580 bacterial effect Effects 0.000 description 2
• 208000022362 bacterial infectious disease Diseases 0.000 description 2
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 102000023852 carbohydrate binding proteins Human genes 0.000 description 2
• 108091008400 carbohydrate binding proteins Proteins 0.000 description 2
• 229960003866 cefaloridine Drugs 0.000 description 2
• CZTQZXZIADLWOZ-CRAIPNDOSA-N cefaloridine Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 230000006037 cell lysis Effects 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 229960001265 ciclosporin Drugs 0.000 description 2
• MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
• 229960004316 cisplatin Drugs 0.000 description 2
• 238000010367 cloning Methods 0.000 description 2
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
• 239000004074 complement inhibitor Substances 0.000 description 2
• 238000012790 confirmation Methods 0.000 description 2
• 208000018631 connective tissue disease Diseases 0.000 description 2
• 238000010276 construction Methods 0.000 description 2
• 208000006111 contracture Diseases 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 229940109239 creatinine Drugs 0.000 description 2
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
• 229930182912 cyclosporin Natural products 0.000 description 2
• 235000018417 cysteine Nutrition 0.000 description 2
• 230000007812 deficiency Effects 0.000 description 2
• 238000012217 deletion Methods 0.000 description 2
• 230000037430 deletion Effects 0.000 description 2
• 230000001627 detrimental effect Effects 0.000 description 2
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
• 208000037765 diseases and disorders Diseases 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• 239000006196 drop Substances 0.000 description 2
• 238000009510 drug design Methods 0.000 description 2
• 230000004064 dysfunction Effects 0.000 description 2
• 208000002296 eclampsia Diseases 0.000 description 2
• 230000007515 enzymatic degradation Effects 0.000 description 2
• 239000003889 eye drop Substances 0.000 description 2
• 229940012356 eye drops Drugs 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• 210000003811 finger Anatomy 0.000 description 2
• 108020001507 fusion proteins Proteins 0.000 description 2
• 102000037865 fusion proteins Human genes 0.000 description 2
• 102000034356 gene-regulatory proteins Human genes 0.000 description 2
• 108091006104 gene-regulatory proteins Proteins 0.000 description 2
• 238000010353 genetic engineering Methods 0.000 description 2
• 229960002518 gentamicin Drugs 0.000 description 2
• 210000000585 glomerular basement membrane Anatomy 0.000 description 2
• 239000004220 glutamic acid Substances 0.000 description 2
• 230000010005 growth-factor like effect Effects 0.000 description 2
• 230000035876 healing Effects 0.000 description 2
• 208000006750 hematuria Diseases 0.000 description 2
• 231100000753 hepatic injury Toxicity 0.000 description 2
• 230000003118 histopathologic effect Effects 0.000 description 2
• 230000002209 hydrophobic effect Effects 0.000 description 2
• 125000001165 hydrophobic group Chemical group 0.000 description 2
• 230000001969 hypertrophic effect Effects 0.000 description 2
• 230000036039 immunity Effects 0.000 description 2
• 230000003053 immunization Effects 0.000 description 2
• 231100000268 induced nephrotoxicity Toxicity 0.000 description 2
• 208000000509 infertility Diseases 0.000 description 2
• 230000036512 infertility Effects 0.000 description 2
• 231100000535 infertility Toxicity 0.000 description 2
• 230000008595 infiltration Effects 0.000 description 2
• 206010022000 influenza Diseases 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
• 210000000936 intestine Anatomy 0.000 description 2
• 208000028867 ischemia Diseases 0.000 description 2
• 230000000302 ischemic effect Effects 0.000 description 2
• 150000002632 lipids Chemical class 0.000 description 2
• 229960001078 lithium Drugs 0.000 description 2
• 229910052744 lithium Inorganic materials 0.000 description 2
• 230000002101 lytic effect Effects 0.000 description 2
• 208000002780 macular degeneration Diseases 0.000 description 2
• 206010025482 malaise Diseases 0.000 description 2
• 239000002609 medium Substances 0.000 description 2
• 230000000813 microbial effect Effects 0.000 description 2
• 230000003278 mimic effect Effects 0.000 description 2
• 230000009456 molecular mechanism Effects 0.000 description 2
• 230000000921 morphogenic effect Effects 0.000 description 2
• 238000010172 mouse model Methods 0.000 description 2
• 229950006780 n-acetylglucosamine Drugs 0.000 description 2
• 230000003589 nefrotoxic effect Effects 0.000 description 2
• 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 2
• 238000003199 nucleic acid amplification method Methods 0.000 description 2
• 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 2
• 230000001662 opsonic effect Effects 0.000 description 2
• 239000001301 oxygen Substances 0.000 description 2
• 229910052760 oxygen Inorganic materials 0.000 description 2
• 230000036407 pain Effects 0.000 description 2
• 244000045947 parasite Species 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 230000007310 pathophysiology Effects 0.000 description 2
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
• 208000001297 phlebitis Diseases 0.000 description 2
• 150000004713 phosphodiesters Chemical group 0.000 description 2
• 150000008300 phosphoramidites Chemical class 0.000 description 2
• 230000036470 plasma concentration Effects 0.000 description 2
• 238000002616 plasmapheresis Methods 0.000 description 2
• 229920000642 polymer Polymers 0.000 description 2
• 229920001282 polysaccharide Polymers 0.000 description 2
• 239000005017 polysaccharide Substances 0.000 description 2
• 238000003825 pressing Methods 0.000 description 2
• 230000000770 proinflammatory effect Effects 0.000 description 2
• 235000019419 proteases Nutrition 0.000 description 2
• 238000000159 protein binding assay Methods 0.000 description 2
• 235000004252 protein component Nutrition 0.000 description 2
• 210000000512 proximal kidney tubule Anatomy 0.000 description 2
• 238000010188 recombinant method Methods 0.000 description 2
• 230000007115 recruitment Effects 0.000 description 2
• 230000008439 repair process Effects 0.000 description 2
• 208000037803 restenosis Diseases 0.000 description 2
• 230000002207 retinal effect Effects 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 239000000523 sample Substances 0.000 description 2
• 230000037387 scars Effects 0.000 description 2
• 208000013220 shortness of breath Diseases 0.000 description 2
• 239000007790 solid phase Substances 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 208000020431 spinal cord injury Diseases 0.000 description 2
• 210000004988 splenocyte Anatomy 0.000 description 2
• 230000002269 spontaneous effect Effects 0.000 description 2
• 230000008961 swelling Effects 0.000 description 2
• 208000011580 syndromic disease Diseases 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 230000008685 targeting Effects 0.000 description 2
• 229940126585 therapeutic drug Drugs 0.000 description 2
• 231100001274 therapeutic index Toxicity 0.000 description 2
• 238000011285 therapeutic regimen Methods 0.000 description 2
• 230000002103 transcriptional effect Effects 0.000 description 2
• 230000009529 traumatic brain injury Effects 0.000 description 2
• 201000008827 tuberculosis Diseases 0.000 description 2
• 230000002485 urinary effect Effects 0.000 description 2
• 210000005166 vasculature Anatomy 0.000 description 2
• 239000013598 vector Substances 0.000 description 2
• 230000002861 ventricular Effects 0.000 description 2
• ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
• UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
• 101710112984 20 kDa protein Proteins 0.000 description 1
• 208000004998 Abdominal Pain Diseases 0.000 description 1
• 208000030090 Acute Disease Diseases 0.000 description 1
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
• 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
• 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
• 101800000415 Acylation stimulating protein Proteins 0.000 description 1
• 102400000630 Acylation stimulating protein Human genes 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• 206010001889 Alveolitis Diseases 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• 229930183010 Amphotericin Natural products 0.000 description 1
• QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
• 108010032595 Antibody Binding Sites Proteins 0.000 description 1
• 108020004491 Antisense DNA Proteins 0.000 description 1
• 102000004411 Antithrombin III Human genes 0.000 description 1
• 108090000935 Antithrombin III Proteins 0.000 description 1
• 235000003911 Arachis Nutrition 0.000 description 1
• 244000105624 Arachis hypogaea Species 0.000 description 1
• QYLJIYOGHRGUIH-CIUDSAMLSA-N Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCNC(N)=N QYLJIYOGHRGUIH-CIUDSAMLSA-N 0.000 description 1
• 206010003658 Atrial Fibrillation Diseases 0.000 description 1
• 102100032306 Aurora kinase B Human genes 0.000 description 1
• 108090000749 Aurora kinase B Proteins 0.000 description 1
• 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
• 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
• 238000011725 BALB/c mouse Methods 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 101150071258 C3 gene Proteins 0.000 description 1
• 101150073986 C3AR1 gene Proteins 0.000 description 1
• 208000004434 Calcinosis Diseases 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• 208000002177 Cataract Diseases 0.000 description 1
• 102000005600 Cathepsins Human genes 0.000 description 1
• 108010084457 Cathepsins Proteins 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 102000000844 Cell Surface Receptors Human genes 0.000 description 1
• 108010001857 Cell Surface Receptors Proteins 0.000 description 1
• 229930186147 Cephalosporin Natural products 0.000 description 1
• 206010008469 Chest discomfort Diseases 0.000 description 1
• 241001502567 Chikungunya virus Species 0.000 description 1
• 108010009685 Cholinergic Receptors Proteins 0.000 description 1
• 208000017667 Chronic Disease Diseases 0.000 description 1
• VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 1
• 235000001258 Cinchona calisaya Nutrition 0.000 description 1
• 108010078804 Classical Pathway Complement C5 Convertase Proteins 0.000 description 1
• 206010053567 Coagulopathies Diseases 0.000 description 1
• 102100023661 Coiled-coil domain-containing protein 115 Human genes 0.000 description 1
• 101710155594 Coiled-coil domain-containing protein 115 Proteins 0.000 description 1
• 108010028780 Complement C3 Proteins 0.000 description 1
• 108010078015 Complement C3b Proteins 0.000 description 1
• 108090000056 Complement factor B Proteins 0.000 description 1
• 102000003712 Complement factor B Human genes 0.000 description 1
• 229940124073 Complement inhibitor Drugs 0.000 description 1
• 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
• 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 1
• 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 1
• 201000006306 Cor pulmonale Diseases 0.000 description 1
• 241000557626 Corvus corax Species 0.000 description 1
• 101150018425 Cr1l gene Proteins 0.000 description 1
• 108050006400 Cyclin Proteins 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
• 101100372758 Danio rerio vegfaa gene Proteins 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• ZMJOVJSTYLQINE-UHFFFAOYSA-N Dichloroacetylene Chemical group ClC#CCl ZMJOVJSTYLQINE-UHFFFAOYSA-N 0.000 description 1
• 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
• 206010013082 Discomfort Diseases 0.000 description 1
• 108010024212 E-Selectin Proteins 0.000 description 1
• 102100023471 E-selectin Human genes 0.000 description 1
• 206010014561 Emphysema Diseases 0.000 description 1
• 102000002045 Endothelin Human genes 0.000 description 1
• 108050009340 Endothelin Proteins 0.000 description 1
• 206010066919 Epidemic polyarthritis Diseases 0.000 description 1
• 208000010201 Exanthema Diseases 0.000 description 1
• 108010087819 Fc receptors Proteins 0.000 description 1
• 102000009109 Fc receptors Human genes 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 108090000270 Ficain Proteins 0.000 description 1
• 241000192125 Firmicutes Species 0.000 description 1
• 206010017533 Fungal infection Diseases 0.000 description 1
• 102000027484 GABAA receptors Human genes 0.000 description 1
• 108091008681 GABAA receptors Proteins 0.000 description 1
• 108091092584 GDNA Proteins 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 206010017711 Gangrene Diseases 0.000 description 1
• 206010060891 General symptom Diseases 0.000 description 1
• 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
• 102000006395 Globulins Human genes 0.000 description 1
• 108010044091 Globulins Proteins 0.000 description 1
• 229930186217 Glycolipid Natural products 0.000 description 1
• 229940126544 HIV-1 protease inhibitor Drugs 0.000 description 1
• 206010061192 Haemorrhagic fever Diseases 0.000 description 1
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
• 206010019663 Hepatic failure Diseases 0.000 description 1
• 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 1
• 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
• 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
• 101000958041 Homo sapiens Musculin Proteins 0.000 description 1
• 101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 description 1
• 102000003839 Human Proteins Human genes 0.000 description 1
• 108090000144 Human Proteins Proteins 0.000 description 1
• 108010016183 Human immunodeficiency virus 1 p16 protease Proteins 0.000 description 1
• 102000004157 Hydrolases Human genes 0.000 description 1
• 108090000604 Hydrolases Proteins 0.000 description 1
• 208000031226 Hyperlipidaemia Diseases 0.000 description 1
• 208000034767 Hypoproteinaemia Diseases 0.000 description 1
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
• 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
• 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
• 102100022339 Integrin alpha-L Human genes 0.000 description 1
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
• 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 102100030698 Interleukin-12 subunit alpha Human genes 0.000 description 1
• 102000003816 Interleukin-13 Human genes 0.000 description 1
• 108090000176 Interleukin-13 Proteins 0.000 description 1
• 108010002350 Interleukin-2 Proteins 0.000 description 1
• 102000000588 Interleukin-2 Human genes 0.000 description 1
• 108090000978 Interleukin-4 Proteins 0.000 description 1
• 102000004388 Interleukin-4 Human genes 0.000 description 1
• 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 1
• 206010023232 Joint swelling Diseases 0.000 description 1
• 206010023421 Kidney fibrosis Diseases 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
• 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
• 102000007547 Laminin Human genes 0.000 description 1
• 108010085895 Laminin Proteins 0.000 description 1
• 108090001030 Lipoproteins Proteins 0.000 description 1
• 102000004895 Lipoproteins Human genes 0.000 description 1
• 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
• 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
• 208000002720 Malnutrition Diseases 0.000 description 1
• 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
• 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
• 206010066453 Mesangioproliferative glomerulonephritis Diseases 0.000 description 1
• 208000029725 Metabolic bone disease Diseases 0.000 description 1
• 229930192392 Mitomycin Natural products 0.000 description 1
• 101710159910 Movement protein Proteins 0.000 description 1
• 206010048723 Multiple-drug resistance Diseases 0.000 description 1
• UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 description 1
• 208000000112 Myalgia Diseases 0.000 description 1
• 208000031888 Mycoses Diseases 0.000 description 1
• 201000002481 Myositis Diseases 0.000 description 1
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
• OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
• MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
• 206010028980 Neoplasm Diseases 0.000 description 1
• 206010029155 Nephropathy toxic Diseases 0.000 description 1
• 101710163270 Nuclease Proteins 0.000 description 1
• 102000011931 Nucleoproteins Human genes 0.000 description 1
• 108010061100 Nucleoproteins Proteins 0.000 description 1
• 206010053159 Organ failure Diseases 0.000 description 1
• 206010049088 Osteopenia Diseases 0.000 description 1
• 208000001132 Osteoporosis Diseases 0.000 description 1
• 108010067372 Pancreatic elastase Proteins 0.000 description 1
• 102000016387 Pancreatic elastase Human genes 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 241000282520 Papio Species 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• 108010067902 Peptide Library Proteins 0.000 description 1
• 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
• 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
• 108010059820 Polygalacturonase Proteins 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 108010005642 Properdin Proteins 0.000 description 1
• 102100038567 Properdin Human genes 0.000 description 1
• 108010076504 Protein Sorting Signals Proteins 0.000 description 1
• 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
• 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
• 101100006979 Rattus norvegicus C4 gene Proteins 0.000 description 1
• 230000010799 Receptor Interactions Effects 0.000 description 1
• 208000031074 Reinjury Diseases 0.000 description 1
• 206010062237 Renal impairment Diseases 0.000 description 1
• 206010063897 Renal ischaemia Diseases 0.000 description 1
• 208000037656 Respiratory Sounds Diseases 0.000 description 1
• 206010057190 Respiratory tract infections Diseases 0.000 description 1
• 108091028664 Ribonucleotide Proteins 0.000 description 1
• 241000710942 Ross River virus Species 0.000 description 1
• 235000014548 Rubus moluccanus Nutrition 0.000 description 1
• 241001222774 Salmonella enterica subsp. enterica serovar Minnesota Species 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• 206010040070 Septic Shock Diseases 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 208000031709 Skin Manifestations Diseases 0.000 description 1
• 206010050207 Skin fibrosis Diseases 0.000 description 1
• 108091081024 Start codon Proteins 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 108700005078 Synthetic Genes Proteins 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
• 206010053615 Thermal burn Diseases 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
• 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
• 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
• FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
• 208000025865 Ulcer Diseases 0.000 description 1
• 108010059993 Vancomycin Proteins 0.000 description 1
• 101150030763 Vegfa gene Proteins 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 101710090398 Viral interleukin-10 homolog Proteins 0.000 description 1
• 206010047700 Vomiting Diseases 0.000 description 1
• 206010047924 Wheezing Diseases 0.000 description 1
• 241000212749 Zesius chrysomallus Species 0.000 description 1
• RRDRHWJDBOGQHN-JWCTVYNTSA-N [2-[(2s,5r,8s,11s,14r,17s,22s)-17-[(1r)-1-hydroxyethyl]-22-[[(2s)-2-[[(2s,3r)-3-hydroxy-2-[[(2s)-2-[6-methyloctanoyl(sulfomethyl)amino]-4-(sulfomethylamino)butanoyl]amino]butyl]amino]-4-(sulfomethylamino)butanoyl]amino]-5,8-bis(2-methylpropyl)-3,6,9,12,15 Chemical compound CCC(C)CCCCC(=O)N(CS(O)(=O)=O)[C@@H](CCNCS(O)(=O)=O)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCNCS(O)(=O)=O)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](CCNCS(O)(=O)=O)NC(=O)[C@H](CCNCS(O)(=O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCNCS(O)(=O)=O)NC1=O RRDRHWJDBOGQHN-JWCTVYNTSA-N 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 230000021736 acetylation Effects 0.000 description 1
• 238000006640 acetylation reaction Methods 0.000 description 1
• 102000034337 acetylcholine receptors Human genes 0.000 description 1
• 229960004150 aciclovir Drugs 0.000 description 1
• MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 125000000641 acridinyl group Chemical class C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 239000011149 active material Substances 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 230000033289 adaptive immune response Effects 0.000 description 1
• 230000004721 adaptive immunity Effects 0.000 description 1
• 238000009098 adjuvant therapy Methods 0.000 description 1
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 210000004712 air sac Anatomy 0.000 description 1
• GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 230000001668 ameliorated effect Effects 0.000 description 1
• 230000009435 amidation Effects 0.000 description 1
• 238000007112 amidation reaction Methods 0.000 description 1
• 229960004821 amikacin Drugs 0.000 description 1
• LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
• 229940126575 aminoglycoside Drugs 0.000 description 1
• 229940009444 amphotericin Drugs 0.000 description 1
• APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 238000000137 annealing Methods 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 230000000798 anti-retroviral effect Effects 0.000 description 1
• 210000000628 antibody-producing cell Anatomy 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
• 239000003816 antisense DNA Substances 0.000 description 1
• 229940027998 antiseptic and disinfectant acridine derivative Drugs 0.000 description 1
• 229960005348 antithrombin iii Drugs 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 206010003119 arrhythmia Diseases 0.000 description 1
• 230000006793 arrhythmia Effects 0.000 description 1
• 230000003126 arrythmogenic effect Effects 0.000 description 1
• 239000010425 asbestos Substances 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• 230000000468 autoproteolytic effect Effects 0.000 description 1
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
• SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 229960000074 biopharmaceutical Drugs 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 206010006451 bronchitis Diseases 0.000 description 1
• 229940046731 calcineurin inhibitors Drugs 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 201000011510 cancer Diseases 0.000 description 1
• 125000001314 canonical amino-acid group Chemical group 0.000 description 1
• 210000001736 capillary Anatomy 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 229960004261 cefotaxime Drugs 0.000 description 1
• AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 1
• 239000006143 cell culture medium Substances 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 210000002421 cell wall Anatomy 0.000 description 1
• 230000007248 cellular mechanism Effects 0.000 description 1
• 230000004700 cellular uptake Effects 0.000 description 1
• 208000015114 central nervous system disease Diseases 0.000 description 1
• 229940124587 cephalosporin Drugs 0.000 description 1
• 150000001780 cephalosporins Chemical class 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 239000002820 chemotaxin Substances 0.000 description 1
• 230000000973 chemotherapeutic effect Effects 0.000 description 1
• 229940044683 chemotherapy drug Drugs 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 208000020403 chronic hepatitis C virus infection Diseases 0.000 description 1
• 229960000724 cidofovir Drugs 0.000 description 1
• LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
• 229960003405 ciprofloxacin Drugs 0.000 description 1
• 230000007012 clinical effect Effects 0.000 description 1
• 208000035850 clinical syndrome Diseases 0.000 description 1
• 229960003009 clopidogrel Drugs 0.000 description 1
• GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
• 229960003920 cocaine Drugs 0.000 description 1
• 229940108538 colistimethate Drugs 0.000 description 1
• 108700028201 colistinmethanesulfonic acid Proteins 0.000 description 1
• 208000004264 complement component 5 deficiency Diseases 0.000 description 1
• 102000006834 complement receptors Human genes 0.000 description 1
• 108010047295 complement receptors Proteins 0.000 description 1
• 230000001010 compromised effect Effects 0.000 description 1
• 238000000205 computational method Methods 0.000 description 1
• 230000008473 connective tissue growth Effects 0.000 description 1
• 239000000356 contaminant Substances 0.000 description 1
• 230000008828 contractile function Effects 0.000 description 1
• 210000004351 coronary vessel Anatomy 0.000 description 1
• 229960001334 corticosteroids Drugs 0.000 description 1
• 229940111134 coxibs Drugs 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 150000001945 cysteines Chemical class 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 230000003413 degradative effect Effects 0.000 description 1
• 239000005547 deoxyribonucleotide Substances 0.000 description 1
• 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
• 230000001066 destructive effect Effects 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
• 210000002249 digestive system Anatomy 0.000 description 1
• 239000000539 dimer Substances 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 230000006334 disulfide bridging Effects 0.000 description 1
• 239000002934 diuretic Substances 0.000 description 1
• 229940030606 diuretics Drugs 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 208000017574 dry cough Diseases 0.000 description 1
• 229960002224 eculizumab Drugs 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 210000001671 embryonic stem cell Anatomy 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
• 210000003989 endothelium vascular Anatomy 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
• 210000003979 eosinophil Anatomy 0.000 description 1
• 150000002118 epoxides Chemical class 0.000 description 1
• 230000010437 erythropoiesis Effects 0.000 description 1
• 210000003238 esophagus Anatomy 0.000 description 1
• 201000005884 exanthem Diseases 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
• 208000010706 fatty liver disease Diseases 0.000 description 1
• LZPBLUATTGKZBH-UHFFFAOYSA-L fenoprofen calcium Chemical compound O.O.[Ca+2].[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1.[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 LZPBLUATTGKZBH-UHFFFAOYSA-L 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 230000003352 fibrogenic effect Effects 0.000 description 1
• 230000009795 fibrotic process Effects 0.000 description 1
• 239000002657 fibrous material Substances 0.000 description 1
• POTUGHMKJGOKRI-UHFFFAOYSA-N ficin Chemical compound FI=CI=N POTUGHMKJGOKRI-UHFFFAOYSA-N 0.000 description 1
• 235000019836 ficin Nutrition 0.000 description 1
• 238000009093 first-line therapy Methods 0.000 description 1
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
• 210000002683 foot Anatomy 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
• 238000002825 functional assay Methods 0.000 description 1
• 230000009760 functional impairment Effects 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 230000030279 gene silencing Effects 0.000 description 1
• 238000012226 gene silencing method Methods 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 230000001434 glomerular Effects 0.000 description 1
• 206010061989 glomerulosclerosis Diseases 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 229960005150 glycerol Drugs 0.000 description 1
• 208000035474 group of disease Diseases 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 125000005179 haloacetyl group Chemical group 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 230000004217 heart function Effects 0.000 description 1
• 210000002443 helper t lymphocyte Anatomy 0.000 description 1
• 210000003494 hepatocyte Anatomy 0.000 description 1
• 235000008216 herbs Nutrition 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 230000009215 host defense mechanism Effects 0.000 description 1
• 102000046949 human MSC Human genes 0.000 description 1
• 210000003917 human chromosome Anatomy 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 230000003301 hydrolyzing effect Effects 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
• 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
• 229960001101 ifosfamide Drugs 0.000 description 1
• 150000002463 imidates Chemical class 0.000 description 1
• 150000002466 imines Chemical class 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 238000002649 immunization Methods 0.000 description 1
• 238000000760 immunoelectrophoresis Methods 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 238000001114 immunoprecipitation Methods 0.000 description 1
• 229960003444 immunosuppressant agent Drugs 0.000 description 1
• 229940125721 immunosuppressive agent Drugs 0.000 description 1
• 229940124589 immunosuppressive drug Drugs 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 230000000415 inactivating effect Effects 0.000 description 1
• 229960001936 indinavir Drugs 0.000 description 1
• CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 230000004941 influx Effects 0.000 description 1
• 210000005007 innate immune system Anatomy 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 229940079322 interferon Drugs 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• 238000004255 ion exchange chromatography Methods 0.000 description 1
• 230000001788 irregular Effects 0.000 description 1
• 230000002427 irreversible effect Effects 0.000 description 1
• 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 210000001503 joint Anatomy 0.000 description 1
• 210000003292 kidney cell Anatomy 0.000 description 1
• 230000005977 kidney dysfunction Effects 0.000 description 1
• 208000037806 kidney injury Diseases 0.000 description 1
• 210000003127 knee Anatomy 0.000 description 1
• 231100000835 liver failure Toxicity 0.000 description 1
• 208000007903 liver failure Diseases 0.000 description 1
• 210000005228 liver tissue Anatomy 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 230000001071 malnutrition Effects 0.000 description 1
• 235000000824 malnutrition Nutrition 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 229960001855 mannitol Drugs 0.000 description 1
• 238000013507 mapping Methods 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 101150011109 mbl gene Proteins 0.000 description 1
• KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
• 229960004963 mesalazine Drugs 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 229960004857 mitomycin Drugs 0.000 description 1
• 239000003607 modifier Substances 0.000 description 1
• 238000000302 molecular modelling Methods 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 210000005087 mononuclear cell Anatomy 0.000 description 1
• 150000002772 monosaccharides Chemical group 0.000 description 1
• 210000003097 mucus Anatomy 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• 230000003680 myocardial damage Effects 0.000 description 1
• 230000002107 myocardial effect Effects 0.000 description 1
• 208000031225 myocardial ischemia Diseases 0.000 description 1
• 210000004165 myocardium Anatomy 0.000 description 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 229940053050 neomycin sulfate Drugs 0.000 description 1
• 238000013059 nephrectomy Methods 0.000 description 1
• 208000009928 nephrosis Diseases 0.000 description 1
• 231100001027 nephrosis Toxicity 0.000 description 1
• 231100000381 nephrotoxic Toxicity 0.000 description 1
• 231100000417 nephrotoxicity Toxicity 0.000 description 1
• 230000007694 nephrotoxicity Effects 0.000 description 1
• GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
• 231100000956 nontoxicity Toxicity 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 125000003835 nucleoside group Chemical group 0.000 description 1
• 231100000862 numbness Toxicity 0.000 description 1
• 208000015380 nutritional deficiency disease Diseases 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 230000000771 oncological effect Effects 0.000 description 1
• 230000014207 opsonization Effects 0.000 description 1
• 230000008816 organ damage Effects 0.000 description 1
• 210000004789 organ system Anatomy 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 238000002640 oxygen therapy Methods 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• FIKAKWIAUPDISJ-UHFFFAOYSA-L paraquat dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1C1=CC=[N+](C)C=C1 FIKAKWIAUPDISJ-UHFFFAOYSA-L 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 230000001991 pathophysiological effect Effects 0.000 description 1
• 150000002960 penicillins Chemical class 0.000 description 1
• XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
• 229960004448 pentamidine Drugs 0.000 description 1
• 239000000816 peptidomimetic Substances 0.000 description 1
• 239000000575 pesticide Substances 0.000 description 1
• 238000002823 phage display Methods 0.000 description 1
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 201000003144 pneumothorax Diseases 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 229920000447 polyanionic polymer Polymers 0.000 description 1
• 238000003752 polymerase chain reaction Methods 0.000 description 1
• 238000006116 polymerization reaction Methods 0.000 description 1
• 102000054765 polymorphisms of proteins Human genes 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 230000002206 pro-fibrotic effect Effects 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 230000002250 progressing effect Effects 0.000 description 1
• 208000037821 progressive disease Diseases 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 230000006916 protein interaction Effects 0.000 description 1
• 238000001243 protein synthesis Methods 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 150000003214 pyranose derivatives Chemical group 0.000 description 1
• 238000012207 quantitative assay Methods 0.000 description 1
• 229960000948 quinine Drugs 0.000 description 1
• 238000010526 radical polymerization reaction Methods 0.000 description 1
• 238000003127 radioimmunoassay Methods 0.000 description 1
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
• 206010037844 rash Diseases 0.000 description 1
• 238000011552 rat model Methods 0.000 description 1
• 239000003642 reactive oxygen metabolite Substances 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 238000004064 recycling Methods 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 230000029058 respiratory gaseous exchange Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 239000002336 ribonucleotide Substances 0.000 description 1
• 125000002652 ribonucleotide group Chemical group 0.000 description 1
• 229910052895 riebeckite Inorganic materials 0.000 description 1
• 229960001225 rifampicin Drugs 0.000 description 1
• JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 230000036303 septic shock Effects 0.000 description 1
• SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 230000037432 silent mutation Effects 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 229960002930 sirolimus Drugs 0.000 description 1
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
• 238000001542 size-exclusion chromatography Methods 0.000 description 1
• 231100000046 skin rash Toxicity 0.000 description 1
• 210000002460 smooth muscle Anatomy 0.000 description 1
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
• 230000003637 steroidlike Effects 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 229960001052 streptozocin Drugs 0.000 description 1
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
• 201000009032 substance abuse Diseases 0.000 description 1
• 229940124530 sulfonamide Drugs 0.000 description 1
• 150000003456 sulfonamides Chemical class 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 229960001967 tacrolimus Drugs 0.000 description 1
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
• 208000009056 telangiectasis Diseases 0.000 description 1
• 238000012360 testing method Methods 0.000 description 1
• 229960000814 tetanus toxoid Drugs 0.000 description 1
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 230000036575 thermal burns Effects 0.000 description 1
• 229920001187 thermosetting polymer Polymers 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• 150000003573 thiols Chemical class 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
• 229960005001 ticlopidine Drugs 0.000 description 1
• PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
• 229960000707 tobramycin Drugs 0.000 description 1
• NLVFBUXFDBBNBW-PBSUHMDJSA-S tobramycin(5+) Chemical compound [NH3+][C@@H]1C[C@H](O)[C@@H](C[NH3+])O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H]([NH3+])[C@H](O)[C@@H](CO)O2)O)[C@H]([NH3+])C[C@@H]1[NH3+] NLVFBUXFDBBNBW-PBSUHMDJSA-S 0.000 description 1
• 210000003371 toe Anatomy 0.000 description 1
• 231100000563 toxic property Toxicity 0.000 description 1
• 231100000041 toxicology testing Toxicity 0.000 description 1
• 210000003437 trachea Anatomy 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
• 230000014621 translational initiation Effects 0.000 description 1
• 238000012384 transportation and delivery Methods 0.000 description 1
• 229960001288 triamterene Drugs 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 231100000397 ulcer Toxicity 0.000 description 1
• MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
• 229960000604 valproic acid Drugs 0.000 description 1
• 229960003165 vancomycin Drugs 0.000 description 1
• MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
• MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
• 208000011733 vascular alteration Diseases 0.000 description 1
• 230000004869 vascular alteration Effects 0.000 description 1
• 230000004218 vascular function Effects 0.000 description 1
• 230000006439 vascular pathology Effects 0.000 description 1
• 230000008728 vascular permeability Effects 0.000 description 1
• 230000006442 vascular tone Effects 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 239000011800 void material Substances 0.000 description 1
• 239000002699 waste material Substances 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 210000000707 wrist Anatomy 0.000 description 1
• 210000005253 yeast cell Anatomy 0.000 description 1